DRα1-MOG-35-55 treatment of Traumatic Brain Injury

Case ID:
Web Published:

Treatment of traumatic brain injury is limited to medications to limit secondary damage to the brain, surgery to relieve pressure on the brain, and rehabilitation. The OHSU discovery uses a proprietary construct comprised of the human leukocyte antigen (HLA)-DRα1 domain linked covalently to mouse (m)MOG-35-55 peptide (DRα1-MOG-35-55 construct) to reduce CNS inflammation and tissue injury in animal models of multiple sclerosis and ischemic stroke. Daily injections of DRα1-MOG-35-55 significantly reduced numbers of infiltrating CD74+ and CD86+ macrophages and increased numbers of CD206+ microglia in the brain concomitant with smaller lesion sizes and improvement in neurodeficits. Conversely, DRα1-MOG-35-55 treatment of TBI increased numbers of circulating CD11b+ monocytes and their expression of CD74 but had no detectable effect on cell numbers or marker expression in the spleen. These results demonstrate that DRα1-MOG-35-55 therapy can reduce CNS inflammation and significantly improve histological and clinical outcomes after TBI. Future studies will further examine the potential of DRα1-MOG-35-55 for treatment of TBI. 

Patent Information:
For Information, Contact:
Michele Gunness
Senior Technology Development Manager
Oregon Health & Science University
(503) 494-8200
Halina Offner-Vandenbark
Arthur Vandenbark
Therapeutics - Neurology
© 2019. All Rights Reserved. Powered by Inteum